Huons Group’s subsidiary Humedix announced on Wednesday its collaboration with Medisarang, a specialist in platelet-rich plasma (PRP) kit development and manufacturing, to jointly pursue new ventures in regenerative medicine using autologous blood.
The previous day, Humedix and Medisarang signed a strategic memorandum of understanding (MOU) at the Huons Group headquarters in Pangyo, Seongnam City, Gyeonggi Province. The agreement focuses on commercializing new PRP kit products and activation platforms.
The partnership aims to collaborate on extracting and activating growth factors and platelets, as well as developing and commercializing related equipment. Both companies are particularly committed to upgrading existing PRP kit products, from planning and development to marketing, distribution, and sales.
Through this business agreement, Humedix plans to significantly expand its footprint in the regenerative aesthetics market, leveraging PRP and activation solutions.
Humedix Chief Executive Officer (CEO) Kang Min-jong stated that this partnership allows us to secure a portfolio that complements the existing aesthetic product line. It aims to accelerate our market entry and expand the business by leveraging synergies with the aesthetic products.
PRP kits are medical devices designed to extract and activate growth factors secreted by platelets from a patient’s own blood. These kits are widely used in various medical fields, including orthopedics, obstetrics, and ophthalmology. Recently, their applications have been expanding into the aesthetic sector.
Medisarang, specializing in PRP kit development and manufacturing, has several products that have received domestic medical device approvals and certifications.
